1 photos
Clotshot: The Aftermath: Part IIX:
UK government data covering weeks 5-8. Of the 3,527 people who died from China Virus, 394 were unclotshotted, 3133 were clotshotted. Case rates per 100,000 were 3 times greater among the clotshotted than unclotshotted in age groups 30-80. Negative efficacy from a DNA altering clotshot using experimental substances that weren't even tested in lab rats to attack a man made virus from 400 years in the future. What could go wrong?
[URL]https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf[/URL]
Do you read your own shit?
[QUOTE=AaronHamlet;5810885]UK government data covering weeks 5-8. Of the 3,527 people who died from China Virus, 394 were unclotshotted, 3133 were clotshotted. Case rates per 100,000 were 3 times greater among the clotshotted than unclotshotted in age groups 30-80. Negative efficacy from a DNA altering clotshot created to attack a man made virus from 400 years in the future using experimental substances that weren't even tested in lab rats. What could go wrong?
[URL]https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf[/URL][/QUOTE][B]Executive Summary:[/B]
[I]Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence.
UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination programme. Details of the vaccine surveillance strategy are set on the page COVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19 vaccines is continuously being monitored by the MHRA. [b]They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2).[/b]
[/I]
[B]Vaccine effectiveness[/B]
[I]Several studies of vaccine effectiveness have been conducted in the UK against different COVID-19 variants. Vaccine effectiveness against symptomatic disease with the Omicron variant is substantially lower than against the Delta variant, with rapid waning.[b] However, protection against hospitalisation remains high, particularly after 3 doses.[/I][/b]